New Pyridopyrimidone Derivatives: Synthesis, Molecular Docking Studies, and Potential Anticancer Activity
- 10 Downloads
A new series of pyrido[2,3-d]pyrimidones incorporated pyrazoles and fused triazoles are synthesized and tested in vitro for cytotoxic effect against cancer cell lines: HePG-2, HCT-116, MCF-7, PC-3, and A-549. Their inhibition of protein kinase is assessed. The highest growth inhibitory (IC50 0.3 µM) effect is determined for one of compounds as compared with doxorubicin (IC50 0.6 µM). A modeling study is performed for approaching the compounds mode of binding and their similarity with the positive control drugs.
Keywordspyridopyrimidones cytotoxic agents molecular docking
Unable to display preview. Download preview PDF.
The project was financially supported by King Saud University, Vice Deanship of Research Chairs.
- 5.Cordeu, L., Cubedo, E., Bandres, E., Rebollo, A., Saenz, X., Chozas, H., Victoria, M., Dominguez, M.V., Echeverria, M., Mendivil, B., Sanmartin, C., Palop, J.A., Font, M., and Garcia-Foncillas, J., Bioorg. Med. Chem., 2007, vol. 15, p. 1659. doi https://doi.org/10.1016/j.bmc.2006.12.010 CrossRefGoogle Scholar
- 7.Khalifa, N.M., Al-Omar, M.A., Alkahtani, H.M., and Bakheit, A.H., Patent, 2018, No.: US 10,100,054 B1.Google Scholar
- 11.Molecular Operating Environment (MOE), 2015.08; Chemical Computing Group Inc.: Montreal, QC, Canada, 2015.Google Scholar